Motixafortide for MRD Sensitization in AML

NCT07392970 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Measurable Residual Disease

Interventions

DRUG: Motixafortide

Sponsor

Washington University School of Medicine

Collaborators

[object Object]